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Or. FR 
By letter of 13 February 1990, the Council consulted the European Parliament, 
pursuant to Article 100a of the EEC Treaty, on the Commission proposal for a 
Council directive on the labelling of medicinal products for human use and on 
package leaflets. 
At the sitting of 12 March 1990, the President of Parliament announced that he 
had referred this proposal to the Committee on the Environment, Public Health 
and Consumer Protection as the committee responsible and to the Committee on 
Economic and Monetary Affairs and Industrial Policy and the Committee on 
Budgets for their opinions. 
At its meeting of 23 March 1990, the Committee on the Environment, Public 
Health and Consumer Protection appointed Mrs ceci rapporteur. 
At its meetings of 30 October, 9 November and 18 December 1990 and 31 January 
and 2 May 1991, it considered the Commission proposal and draft report. 
At the last meeting it adopted the draft legislative resolution unanimously. 
The following took part in the vote: Collins, chairman; Schleicher, vice-
chairman; Ceci, rapporteur; Alber, Bertens, Bowe, Chanterie, Douste-Blazy, 
Florenz, Guidolin, Jepsen (for caroline Jackson), Lannoye (for Amendola), 
Maher (for Pereira), Monnier-Besombes, Muntingh, Partsch, Pollack, Pronk (for 
Banotti), Puerta, Randzio-Plath (for Avgerinos), Simmonds, Valverde Lopez, 
Veil, Vohrer and Wilson (for Bombard). 
The op4n4ons of the Committee on Economic and Monetary Affairs and Industrial 
Policy and the Committee on Budgets are attached. 
The report was tabled on 7 May 1991. 
The deadline for tabling amendments will appear on the draft agenda for the 
part-session at which the report is to be considered. 
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A 
Commission proposal for a Council directive on the 
labelling of medicinal products for 
human use and on package leaflets 
Commission text1 Amendments 
(Amendment No. 1) 
Fifth recital 
whereas the prov~s~ons governing the 
information supplied to users should 
provide a high degree of consumer 
protection, in order that medicinal 
products be used correctly on the 
basis of complete and comprehensive 
information; 
whereas the prov~s~ons governing the 
information supplied to users should 
provide a high degree of consumer 
protection, in order that medicinal 
products be used correctly on the 
basis of complete and comprehensive 
information, and whereas those 
provisions should be worded in such 
a way as to provide clear and 
intelligible information that can 
prevent medical products from being 
used incorrectly and identify 
possible contra-indications clearly; 
(Amendment No. 2) 
Fifth recital a (new) 
whereas the provisions should be 
available to users at all times in 
the language of their Member State; 
whereas a translation should be 
provided if the provisions have been 
drawn up in a language other than 
the customary language of the Member 
State concerned; 
1 For full text see COM(89) 607 final - OJ No. C 58, 8.3.1990, p.21 
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Commission text 
DOC_EN\RR\109304 
Amendments 
(Amendment No. 3) 
Seventh recital a (new) 
whereas clear labelling and clear 
packaae leaflets do not dispense 
with the need to protect customers' 
health, given that responsibility 
for promoting correct use of 
medicines remains with the doctor 
and/or the pharmacist and the health 
services; 
(Amendment No. 4) 
Seventh recital b (new) 
whereas medicines available on 
prescription only and medicines 
available over the counter require 
different kinds of information to be 
provided insofar as there are 
differences in respect of their 
particulars, their methods of use 
and prescribed responsibilities; 
(Amendment No. 5) 
Seventh recital c (new) 
whereas the necessity to monitor 
medicinal products does not end in 
the experimental pre-clinical stage 
nor when the product is introduced 
onto the market, and whereas 
adeauate monitorina of medicinal 
products under the responsibility of 
authorized persons provides the best 
guarantee for consumer protection; 
(Amendment No. 6) 
Seventh recital d (new) 
- 5 -
whereas industry has an obligation 
to cooperate in providing effective 
information and monitoring medicinal 
products, in particular by ensuring 
that undesired side-effects are made 
known as widely as possible; 
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Or. FR 
Commission text Amendments 
(Amendment No. 7) 
Article 1(1) 
1. This directive deals with the 
labelling of medicinal products for 
human use and leaflets inserted in 
packages of such products. 
1. This directive deals with the 
labelling of medicinal products for 
human use and leaflets inserted in 
packages of such products. Its aim 
is to provide consumers with clear, 
comprehensible and comprehensive 
information compiled in such a way 
as to prevent incorrect use of 
medicines. 
(Amendment No. 8) 
Article 1(2), first indent 
- "name of the medicinal product" 
shall mean the name given to a 
medicinal product, which may be an 
invented name or a common chemical 
name together with a trademark or 
the name of the manufacturer; 
- "name of the medicinal product" 
shall mean the name given to a 
medicinal product, which may be an 
invented name or a common chemical 
name together with a trademark or 
the name of the manufacturer; in 
the case of an invented riame, this 
shall not be confused with the 
common name; 
(Amendment No. 9) 
Article 1(2), fifth indent a (new) 
- "labelling" shall mean the 
particulars provided on the outer 
or immediate packaging; 
(Amendment No. 10) 
Article 3(a) 
a) The name of the medicinal product, 
including or followed by the common 
name if the product contains only one 
active ingredient; 
a) the name of the medicinal 
product, including or followed by 
the international common name; 
(Amendment No. 11) 
Article 3(d) 
d) a list of the excipients; 
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to ensure an 
of the medicinal 
PE 145.361/fin. 
or. FR 
Commission text 
(Amendment No. 12) 
Article 3(ed) (new) 
Amendments 
ed) special warnings including 
categories of users for whom the 
product is unsuitable and potential 
effects on ability to operate 
machinery; 
(Amendment No. 13) 
Article 3(f) 
f) a special warning that the product 
must be stored out of reach of 
children; 
f) a special warning, in a highly 
visible location provided for 
this purpose, that the product 
must be stored out of reach of 
children; 
(Amendment No. 14) 
Article 3(g) 
g) the expiry date in clear terms 
<month/year); 
g) the period for which 
extemporaneous preparations may 
be kept after being 
reconstituted, and an inset for 
notes on this by the user; 
(Amendment No. 15) 
Article 3(ga) (new) 
ga) the length of time and the 
temperature for storage after being 
reconstituted for medicinal products 
presented in multiple doses and 
prepared extemporaneously; 
(Amendment No. 16) 
Article 3(h) 
h) special storage precautions, if 
any; 
h) special storage precautions, if 
any, including the length of time 
the product may be kept after 
opening; 
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Commission text 
(Amendment No. 17) 
Article 3(i) 
Amendments 
i) special precautions for disposal 
of unused medicinal products or 
waste materials derived from such 
products, if appropriate; 
i) special precautions for disposal 
of unused medicinal products 
whose shelf life has expired or 
waste materials derived from such 
products, if appropriate; 
(Amendment No. 18) 
Article 3(j) 
j) the name and address of the person 
responsible for placing the 
medicinal product on the market 
and, where different, of the 
manufacturer; 
j) the name and address 
person responsible for 
the medicinal product 
market; 
of the 
placing 
on the 
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(Amendment No. 19) 
Article 3(la) (new) 
la) advice, where appropriate, to 
•read the enclosed leaflet•; 
(Amendment No. 20) 
Article 3(lb) (new) 
lb) the price of the medicinal 
product 'immediate packaging only'; 
(Amendment No. 21) 
Article 3(lc) (new) 
- 8 -
le) the words 'on prescription 
onlv' in connection with medicinal 
products which may be supplied only 
on prescription from a medical 
practitioner; 
the words 'pharmacy onlv' in 
connection with medicinal products 
which may be supplied to the 
consumer in pharmacies only; 
the words •sample - not for sale' in 
connection with medicinal products 
which may supplied as a 
complimentary sample to persons 
entitled to prescribe or supply the 
products concerned'; 
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Commission text 
(Amendment No. 22) 
Article 3(2) and (3) (new) 
Amendments 
2. The Commission shall appoint a 
Eurooean Community body 
established by Council Regulation 
<EEC) No. to devise 
pictograms for inclusion on the 
outer packaging of medicinal 
products, in connection with: 
- psychotropes and narcotics, 
- any habit-forming and/or 
addictive medicinal product, 
- any illicit drug product 
included on the Council of 
Eurooe or International Olympic 
Committee list. 
3. The body referred to in paragraph 
2 shall also be responsible for 
devising pictograms for inclusion 
on the outer packaging of 
medicinal products in connection 
with special user categories, in 
particular, children, pregnant or 
breast-feeding women, the elderly 
or persons with specific 
pathological conditions. 
(Amendment No. 23) 
Article 3a (new) 
3a) Where a medicinal product is 
available with a number of different 
doses of the active ingredient or 
ingredients, the packaging for the 
variants shall be clearly colour 
contrasted. The same graphic 
representations may be used, 
however_. 
(Amendment No. 24) 
Article 4(1) 
1. The following particulars shall 
appear on immediate packagings 
placed in an outer packaging which 
complies with the requirements 
laid down in Article 3: 
1. :.:A:..:t:._...___,l=-e=-=a:...:s:...t:.. the following 
particulars shall appear on 
immediate packagings placed in an 
outer packaging which complies 
with the requirements laid down 
in Article 3: 
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Commission text Amendments 
(Amendment No. 25) 
Article 4{1), second indent a (new) 
in the case of products available 
without prescription, conditions 
for which the product is 
intended, and instructions for 
Y.B,; 
(Amendment No. 26) 
Article 4(1), third indent a (new) 
special warnings including 
categories of users for whom the 
product is unsuitable and 
potential effects on ability to 
operate machinery; 
(Amendment No. 27) 
Article 4{1), third indent b (new) 
the storage period and 
temperature for multiple dose 
extemporaneous medicinal products 
after they have been 
reconstituted, 
(Amendment No. 28) 
Article 4{2) 
2. Paragraph 1 shall not apply to 
immediate packagings containing a 
single dose which are too small to 
contain all the particulars listed 
in paragraph 1. 
2. Immediate packagings which are 
too small to carry all the 
particulars listed in Article 3 
shall carrv at least the 
following particulars: 
DOC EN\RR\109304 
- name of the medicinal product, 
- route and method of 
administration, 
- expiry date, 
- batch number, 
- contents by weight, by volume or 
by number of doses. 
(Amendment No. 29) 
Article 4(2a) (new) 
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2a. Immediate packagings other than 
those referred to in the following 
paragraphs shall carry the 
particulars laid down in Article 3. 
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Commission text Amendments 
(Amendment No. 30) 
Article 5(1) 
1. The particulars referred to in 
Articles 3 and 4 shall be easily 
visible, clearly comprehensible 
and indelible. 
1. The particulars referred to in 
Articles 3 and 4 shall be easily 
visible, clearly comprehensible 
- through the use, if possible, 
of pictograms and colour coding 
- and indelible. 
(Amendment No. 31) 
Article 5(3) 
3. The particulars listed in Article 
3 shall appear in the official 
language or languages of the 
Member State where the product is 
to be put on the market. This 
provision shall not prevent these 
particulars from being indicated 
in various languages, provided the 
information given is the same in 
all languages used. 
3. The particulars listed in Article 
3 shall appear in the official 
language or languages of the 
Member State where the product is 
to be sold. This provision 
shall not prevent these 
particulars from being indicated 
in various languages, provided 
the information given is the same 
in all languages used. 
(Amendment No. 32) 
Article 6(2), third indent a (new) 
special warnings for safe and 
effective use of the medicinal 
product. 
(Amendment No. 33) 
Article 7 
The inclusion in the packaging of 
medicinal products of a package 
leaflet for the information of users 
shall be obligatory unless all the 
information required by Article 8 is 
directly conveyed on the outer 
packaging or on the immediate 
packaging. 
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The inclusion in the packaging of 
medicinal products of a package 
leaflet for the information of users 
shall be obligatory unless all the 
information required by Article 8 is 
directly conveyed on the outer 
packaging or on the immediate 
packaging or unless the medicinal 
product may be administered only by 
a health professional. 
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Commission text Amendments 
(Amendment No. 34) 
Article 8(1)(a), first and second indents 
1. The leaflet shall include, usually 
in the following order: 
a) for the identification of the 
medicinal product: 
name of the medicinal product 
quantitative and qualitative 
composition in terms of active 
ingredients, using the common 
names, 
1. The leaflet shall be drawn up in 
accordance with the summary of 
product characteristics; it shall 
contain, usually in the 
following order: 
a) for the identification of the 
medicinal product: 
name of the medicinal product 
in accordance with Article 
~ 
full quantitative and 
qualitative composition in 
terms of active ingredients and 
excipients, using the common 
names, 
(Amendment No. 35) 
Article 8(l)(a), second indent a (new) 
pharmaceutical form and contents 
by weight, by volume or by dosage 
units, 
(Amendment No. 36) 
Article 8(1)(a), third indent 
- pharmaco-therapeutic group, if 
there exists a term easily 
comprehensible for the patient, 
pharmaco-therapeutic group, or 
type of action, if there exists a 
term easily comprehensible for 
the patient, or, if not, an 
indication of this category in 
terms of a simple description of 
what it covers 
(Amendment No. 37) 
Article 8(1)(a), fourth indent 
- name and address of the holder of 
the marketing authorization, and, 
where different, of the 
manufacturer; 
name and address of the holder of 
the marketing authorization; 
(Amendment No. 38) 
Article 8(1)(b) 
b) + therapeutic indications; 
DOC \RR\109304 - 12 -
b) the therapeutic indications and 
pharmacological characteristics; 
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Commission text Amendments 
(Amendment No. 39) 
Article 8(1) (d) 
d) the necessary instructions for 
proper use, in particular: 
the usual dose and maximum dose, 
the method and route of 
administration, 
the frequency of 
specifying if 
appropriate time 
medicinal product 
be administered; 
administration, 
necessary the 
at which the 
should or must 
and, as appropriate, depending on 
the nature of the product 
the duration of treatment, when it 
should be limited, 
the action to undertake in the 
case of overdose (symptoms, 
emergency procedures, antidotes), 
the course of action to take when 
a dose has not been taken, 
the way the treatment should be 
stopped, if stopping the treatment 
may lead to withdrawal effects; 
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d) the necessary instructions for 
proper use, in particular: 
the usual dose, together with 
wording indicating that this 
does not applv for different 
doses being prescribed, and, if 
possible, the maximum dose 
together with a warning that 
the dose and therapeutic 
procedure may be modified by 
the prescriber; 
the method 
administration, 
and route of 
the frequency of 
administration, specifying if 
necessary the appropriate time 
at which the medicinal product 
should or must be administered; 
and, as appropriate, depending on 
the nature of the product 
the duration of treatment, when 
it should be limited, 
the nature and expected effect 
of using the medicinal product, 
the action to undertake in the 
case of overdose (symptoms, 
emergency procedures and 
antidotes where they exist 
together with an express 
recommendation not to use them 
except under medical control), 
the course of action to take 
when a dose has not been taken, 
the way the treatment should be 
stopped, if stopping the 
treatment may lead to 
withdrawal effects; 
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Commission text Amendments 
(Amendment No. 40) 
Article 8(1)(d) seventh indent a (new) 
an emergency telephone number of 
a toxicology service; 
(Amendment No. 41) 
Article 8(1)(e) 
e) a description of the undesirable 
effects which can occur under 
normal use of the medicinal 
product, with indication if 
possible of their importance, and 
if necessary the action to be 
taken in such case; if the 
medicine is new, the patient 
should be expressly invited to 
communicate any undesirable effect 
which is not mentioned in the 
leaflet to his doctor or to his 
pharmacist; 
e) a description of the undesirable 
effects which can occur when the 
medicinal product is used, with 
indication if possible of their 
importance, and if necessary the 
action to be taken in such case; 
the patient should be expressly 
invited to communicate any 
undesirable effect which is not 
mentioned in the leaflet to his 
doctor or to his pharmacist; 
(Amendment No. 42) 
Article 8(1)(e)(new) 
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e) the necessary instructions in the 
event of a mistake in dosage. 
Clear reference must be made to 
the risk attaching to overdose 
or a sudden interruption in 
treatment especially, if acute 
withdrawal symptoms can be 
identified, by recommending an 
immediate visit to the doctor 
providing treatment or, if 
necessary, to the nearest 
health centre; 
(Amendment No. 43) 
Article 8(1)(f) third indent a (new) 
information as to where, 
following treatment, the 
organization can collect the 
unused portion of the medicinal 
product, with a view to 
preventing it from dispersing 
into the environment; 
(Amendment No. 44) 
Article 8(1)(ga)(new) 
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Conunission text Amendments 
gal the date on which the package 
leaflet was last revised; 
(Amendment No. 45) 
Article 8(2) 
Notwithstanding point l<bl, the 
competent authorities may decide that 
certain therapeutic indications will 
not be mentioned in the package 
leaflet, when the dissemination of 
such information might have serious 
disadvantages for the patient. 
Deleted 
(Amendment No. 46) 
Article 9 
The package leaflet must be written 
in clear and understandable terms for 
the patient, in the official language 
or languages of the Member State 
where the medicinal product is put on 
the market. This provision does not 
prevent the leaflet being printed in 
several languages, provided that the 
same information is given in all the 
languages used. 
The package leaflet must be written 
in such a way that it is clear, 
easily legible and understandable 
for the patient ••• (rest unchanged) 
(Amendment No. 47) 
Article lOa (new) 
DOC_EN\RR\109304 
Draft labelling and leaflets shall 
be drawn up under the authority of a 
medical practitioner and a 
pharmacist. 
(Amendment No. 48) 
Article 11, before paragraph 1 (new) 
- 15 -
Member States shall ensure that the 
marketing authorization authorities 
avail themselves of the assistance 
of representatives of the public 
when examining specimens or mock-ups 
of the outer packaging, the 
inunediate packaging and the draft 
package leaflet. 
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Commission text Amendments 
(Amendment No. 49) 
Article 11(1) 
1. one or more specimens or mock-ups 
of the outer packaging and the 
immediate packaging of a medicinal 
product, together with the draft 
package leaflet, shall be 
submitted to the competent 
authorities of the Member State 
concerned. 
1. One or more specimens or mock-ups 
of the outer packaging and the 
immediate packaging of a 
medicinal product, together with 
the draft package leaflet, 
compiled in accordance with the 
summary of product 
characteristics referred to in 
Article 4a of Directive 
65/65/EEC, shall be submitted to 
the competent authorities of the 
Member State concerned. 
(Amendment No. 50) 
Article 12 ( 1) 
1. When the provisions of this 
directive are not observed, the 
competent authorities of a Member 
State may suspend or revoke the 
authorization to place the 
medicinal product on the market, 
until the labelling and leaflet of 
the medicinal product in question 
has complied with the 
requirements of this Directive. 
1. When the provisions of this 
directive are not observed, the 
competent authorities of a Member 
State shall, by the deadline 
specified in that order, impose 
penalties of a sufficiently 
deterrent nature, which may even 
involve, in the most serious 
instances, suspension of the 
authorization to place the 
medicinal product on the market, 
this to remain in force until the 
labelling of and/or leaflet for 
the medicinal product complies 
with the provisions of this 
Directive. 
Member States shall incorporate 
into their body of law the 
infringements and penalties 
required for the application of 
this article. 
(Amendment No. 51) 
Article 13, introductory phrase 
As necessary, the Commission shall 
publish guidelines concerning: 
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No later than two years after the 
adoption of this Directive, the 
Commission shall publish guidelines 
for the various leaflet sections, in 
particular concerning: 
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Commission text Amendments 
DOC_EN\RR\109304 
(Amendment No. 52) 
Article 13, fourth indent, (new) 
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excipients that must be indicated 
on the packaging and warnings 
referring to them that must be 
carried on the packaging. 
PE 145.361/fin. 
Or. FR 
DRAFT LEGISLATIVE RESOLUTION 
(Cooperation procedure: first reading) 
embodying the opinion of the European Parliament on the Commission proposal 
for a Council directive on the labelling of medicinal products for human use 
and on package leaflets 
The European Parliament, 
- having regard to the commission proposal to the Council (COM(89) 607 final 
- SYN 231) 1 I 
- having been consulted by the Council pursuant to Article lOOa of the EEC 
Treaty (C3-50/90), 
- having regard to the report of the Committee on the Environment, Public 
Health and Consumer Protection and the opinions of the Committee on 
Economic and Monetary Affairs and Industrial Policy and the Committee on 
Budgets (A3-0126/91), 
1. Approves the Commission proposal subject to Parliament's amendments and in 
accordance with the vote thereon; 
2. Calls on the Commission to amend its proposal accordingly, pursuant to 
Article 149(3) of the EEC Treaty; 
3. Calls on the Council to incorporate Parliament's amendments in the common 
position that it adopts in accordance with Article 149(2) (a) of the EEC 
Treaty; 
4. Instructs its President to forward this opinion to the Council and 
Commission. 
1 OJ No. C 58, 8.3.1990, p. 21 
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EXPLANATORY STATEMERT 
Although the main aim of this directive is to rationalize and harmonize the 
labelling of medicinal products and on package leaflets, its main effect is to 
bring about a maior innovation in the provision of information. 
The traditional package leaflet is basically a rewording of the technical 
specifications and, as such, is designed for the attention of the doctor. The 
new leaflet, however, is intended to be of use for the consumer. 
However, in its traditional form the leaflet has been shown to be inadequate. 
This is not the appropriate means for informing the doctor (who needs to be 
informed at the time of prescribing the medicine and not when the drug is 
obtained at the pharmacy), nor for the patient for whom 90% of the highly 
technical information contained in the leaflet is virtually meaningless. 
This directive therefore acknowledges a real need for clarity of information 
and, if nothing else, should encourage good user habits among patients. 
Despite the clear advantages of providing information for consumers which is 
'clear, comprehensible and able to prevent incorrect use of medicines', it 
must be remembered that the new leaflet does not dispense with the need for 
the doctor and/or the pharmacist to provide information since the central role 
played by them in determining doses and the means for administering them 
cannot be discounted. 
It is surprising that the transformation of the leaflet into an instrument for 
providing consumers with information has not been matched by measures to 
harmonize, qualify and control the regulations relating to the scientific 
information provided for the health services and, in particular, doctors. 
Reference to these problems is actually contained in another directive under 
consideration (COM(90) 212 SYN 273). This directive deals with the 
advertising of medicinal products which involves the provision of information 
for the health services since, as the Commission states, 'advertising of 
medicinal products to persons qualified to prescribe or supply them 
contributes to the information available to such persons' (sixth recital) 2 • 
This arrangement, and the operational proposals deriving therefrom, are, quite 
frankly, not tenable. 
Publicity and information, insofar as they have totally different aims and 
objectives, should be clearly and explicitly differentiated and thus regulated 
separately starting with a clear recognition of their distinct aims. 
On the other hand, the subject matter of the two directives under 
consideration should be viewed basically as a single topic that would be 
better defined as 'information for correct use of medicines'. 
Examining the proposals referred to, it is clear that the one on advertising 
of medicinal products is general in nature, in other words aimed at the 
general public, through the traditional means of communication (press, radio, 
2 OJ No. c 163, 4.7.1990, p. 163 
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television); the other proposal on labelling and package leaflets is also 
concerned with information, but is aimed at the user and is therefore 
concerned with all the information required by the consumer to ensure correct 
use of medicine. 
In the specific case of products for self-medication, the similarity and 
overlap of information is even more obvious. 
Indeed, the main aim of advertising is to draw attention to the fact that the 
product exists, while the information provided with the packaging (container 
and leaflets) enables the medicine to be taken with a full knowledge of all 
its particulars (warnings, precautions for use). 
Even scientific information, aimed at the prescribing doctor and dealt with in 
the context of the directive on advertising, should be viewed as information 
aimed at promoting proper use. 
This information is neither condensed, nor strictly commercial in nature. It 
must be drawn up in a rigorous scientific manner to ensure that medicinal 
products are prescribed responsibly and their results monitored. 
The role played by the pharmacist in promoting rational use of medicines is 
just as important. However, in many or in all Community countries, 
pharmacists are currently facing a professional identity crisis. 
This would appear to be due, on the one hand, to the growth of sales outside 
pharmacies and, on the other hand, to the prevailing view of the pharmacy as a 
commercial outlet rather than a health centre. 
The rapporteur takes the view that it is in the interest of public health and 
consumers for the pharmacy to retain its health-oriented role, and as self-
medication spreads, this role should take on greater significance in a 
technical and health context. 
Finally, information relating to the proper use of medicines should take 
different forms depending on whether it is aimed at doctors, pharmacists or 
consumers and depending on whether the medicines are available only on 
prescription or are available over the counter. 
The scope of the present directive concerns information to be provided for 
consumers on labels and package leaflets. 
DOC EN\RR\109304 - 20 - PE 145.361/fin. 
Or. FR 
1. PRODUCTS AVAILABLE ONLY OH PRESCRIPTION 
Medicinal products available only on prescription have extremely specific 
pharmacological properties and are used in well-defined medicinal forms under 
direct medical control. 
1.1. Information for patients 
1.1.1. Information for patients by means of the package leaflet 
Only essential information should be given on package leaflets. It is 
therefore up to the doctor to explain the advantages and disadvantages of the 
medicine that he considers useful to the patient having regard to the 
psychological and physical characteristics of the person under his care. The 
doctor is therefore responsible for providing personalized information in the 
same way that other medical advice (dosage, method of administration, etc.) is 
indicated on an ad personam basis. 
The package leaflet must therefore contain the following headings, in 
particular: 
1.1.1.1. Brief general pharmaco-toxicological explanation. In a few lines 
the text must contain the chemical and pharmacological characteristics of the 
medicinal products, without mentioning other similar substances and without 
providing information liable to encourage the patient to effect self-
treatment; 
1.1.1.2. Therapeutic indications. The text should mention all the 
therapeutic indications as authorized by the registering bodies. 
In any case, the particulars should refer solely to illnesses, without mention 
of any possible symptoms. 
1.1.1. 3. Secondary and collateral effects. Indication of secondary and 
collateral effects must be strictly limited to those situations: a) which 
appear frequently; b) which are serious enough to constitute a threat to the 
patient's life or affect the functioning of his organs and limbs. 
1.1.1.4. Contra-indications. The explanation of contra-indications should be 
limited to those conditions whose epidemiological concomitant with the medical 
condition for which the medicine is taken can be easily identified. 
1.1.1.5. Incompatibility. Particulars must be given of incompatibility with: 
a) specific foods using a correct, but simple terminology; b) Specific 
medicines, with particular reference to products that can be purchased over 
the counter. 
1.1.1. 6 Quantitative and qualitative composition. This composition must 
refer solely and only to the active ingredient. In the case of excipients or 
vehicles only the overall weight (in grams) or volume (in ml) should be 
indicated generically, without any individual analytical particulars. 
1.1.1.7. Pharmaceutical forms, dosaae and precautions for use. The 
particulars in this respect must be clear, but kept to what is absolutely 
essential so that, in the event of any variations in dosage, method of 
administration etc., the patient must consult the doctor. 
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1.1.1.8. Shelf life and storage precautions. This information is useful for 
the patient and should therefore be explained at length. 
1.1.1.9. other information. As is the case for all medical specialities, the 
package leaflet should contain: 
the registration number and the issuing authority; 
name and address of the holder of the marketing authorization; 
name and address of the manufacturer; 
date of manufacture and expiry date; 
an indication as to whether the medicine is listed on European (or 
national) drug tables; 
clear indication in red letters of the system for distributing the 
medicine to the public with the words 'available only on prescription'. 
1. 1. 2 • Information to patients on the outer packaging and the internal 
container (bottle, blister pack, etc.). 
It is absolutely essential that this packaging carry information, but it 
should be such that it does not give rise to confusion about the contents. 
1.1.2.1. Outer packaging. On the two largest sides of the outer packaging 
(or, at any rate, on two sides in the case of a four-sided container) the 
following particulars must appear: 
the invented name; 
the official name of the active ingredient; 
possibly, the weight of the active ingredient; 
the manufacturer's name; 
a statement in red letters that the medicine 
prescription and, possibly, a note to the 
prescriptions cannot be given. 
is available only on 
effect that repeat 
On the other sides, the following particulars must appear: 
the registration holder; 
the manufacturer's address; 
date of manufacture and expiry date; 
a reminder to the consumer that further information can be found on the 
enclosed leaflet. 
1.1.2.2. Internal container. The following particulars must appear on the 
internal container: 
the invented name; 
the official name of the active ingredient; 
possibly, the weight of the active ingredient; 
the manufacturer's name; 
statement in red letters that the drug is available on prescription 
only. 
If the internal container is a blister pack, it must show clearly: 
the invented name; 
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possibly, the weight of the active ingredient which must be legible 
regardless of the number of units used by the patient. 
2. OVBR TBB COUNTER PRODUCTS 
Certain types of pharmaceutical preparations that can be recommended or 
requested directly by the pharmacist or requested directly by the patient for 
self-medication do not require a prescription. 
The preparations concerned are mainly antineuralgics, 
antipruritic&, etc. 
antiseptics, 
Contrary to common belief, OTC preparations cannot be used without special 
precautions. Although such preparations are traditionally free of major 
risks, they are nonetheless not completely harmless. In the final analysis, 
consumers should be informed of the risks entailed so that they can control 
their medication. 
Consequently, the information supplied to the consumer should be particularly 
detailed. 
2.1.1. Information for consumers on the package leaflet 
The information provided on package leaflets should be kept simple so that 
consumers can understand it. Obviously, more detailed information can be 
provided by the doctor or pharmacist. 
The package leaflet should therefore contain the following headings and 
information. 
2.1.1.1. Brief general pharmaco-toxicological explanation. In a few lines 
the text must contain essential information on the chemical and 
pharmacological characteristics of the medicine, without mentioning other 
similar substances and without providing information liable to encourage the 
patient to effect self-treatment involving other medicines. 
2.1.1.2. Therapeutic indications. The text should mention all the 
therapeutic indications as authorized by the registering bodies. 
In any case, the particulars should refer solely to symptoms to be treated by 
the medicine and make no reference whatsoever to possible treatment of acute 
or chronic conditions. 
2.1.1.3. Secondary and collateral. Indication of secondary and collateral 
effects must be strictly limited to those situations: a) which appear 
frequently; b) which are serious enough to constitute a threat to the 
patient's life or affect the functioning of his organs and limbs. 
2.1.1.4. Contra-indications. The explanation of contra-indications should be 
limited to those symptoms whose epidemiological concomitant with the 
symptomatology for which the medicine is taken can be easily identified. 
2.1.1.5. Incompatibility. Particulars must be given of incompatibility with: 
a) specific foods using a correct, but simple terminology; b) specific 
medicines, with particular reference to products that can be purchased over 
the counter; 
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2 .1.1. 6. Quantitative and qualitative composition. This composition must 
refer solely and only to the active ingredient. In the case of excipients or 
vehicles only the overall weight (in grams) or volume (in ml) should be 
indicated generically, without any individual analytical particulars. 
2.1.1.1. Pharmaceutical forms, dosaae and precautions for use. The 
particulars in this respect must be simple, clear and absolutely essential so 
that, in the event of any clarification being needed as regards dosage, method 
of administration etc., the patient must consult the pharmacist or doctor. 
2.1.1.8. Shelf life and storage precautions. This information is useful for 
the patient and should therefore be explained at length. 
2.1.1.9. Other information. As is the case for all medical specialities, the 
package leaflet should contain: 
the registration number and the issuing authority; 
name and address of the holder of the marketing authorization; 
name and address of the manufacturer; 
date of manufacture and expiry date. 
In the light of the above, a centralized structure (Agency) should be 
established to guarantee the suitability of and control over information. The 
provision for publishing specific guidelines 'as necessary' for certain 
categories of drugs would appear totally inadequate. 
This centralized structure should ensure the necessary measures relating to 
the monitoring of medicines underlining the need to move away from an ad hoc 
(as referred to in Article B(c)) to a structured approach (as called for in 
the proposal for a directive). 
GENERAL REMARKS 
The directive puts forward valid measures for improving the use of medicines 
by consumers. 
However, this is not the end of the story. 
Consideration should also be given to: 
(a) coordinating these measures with other measures already proposed by the 
Commission (advertising - Agency - legal regulations) 
(b) the need to define certain aspects to which attention has already been 
drawn (scientific information- monitoring of medicines). 
The proposed amendments aim to provide a firm basis for this linkage and 
strengthen the proposal's information/educational role. In this connection, 
attention should also be given to certain requirements and specific 
suggestions put forward by the parties concerned (consumers, industry, etc.). 
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(Rule 120 of the Rules of Procedure) 
of the Committee on Economic and Monetary Affairs and Industrial Policy for 
the Committee on the Environment, Public Health and Consumer Protection 
Draftsman: Mr SIS6 CRUELLAS 
At its meeting of 27 June 1990, the committee on Economic and Monetary Affairs 
and Industrial Policy appointed Mr Sis6 Cruellas draftsman. 
At its meetings of 26-28 June, 25 and 27 September and 15-16 OCtober 1990, the 
committee considered the draft opinion. On 15 OCtober, it adopted the 
conclusions by 20 votes with one abstention. 
The following took part in the vote: Beumer, chairman; Fuchs, vice-chairman; 
Joaquin Sis6 Cruellas, rapporteur; Cassidy, Cox, Ernst de la Graete, Herman, 
Lulling, Merz, Metten, Pinxten, Rogalla, Speciale, Amaral (for Donnea), 
Martinez (for Megret), Nielsen (for Visentini), Peter (for Ford), Randzio-
Plath (for Hoff), Titley (for Seal), Van der Waal (For Lataillade) and Navarro 
(for Gallenzi), pursuant to Rule 111(2) of the Rules of Procedure. 
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Proposal for a directive on the labelling of medicinal products for human use 
and on package leaflets 
1. Contents of the proposal 
The aim of this proposal is to complete and lay down procedures governing 
labelling and leaflets already dealt with by previous directives3 • 
(a) Labelling 
Articles 3 to 6 deal in particular with: 
- the particulars that must appear on the outer or immediate packaging 
(ingredients, name, etc.), 
- the way in which this information must be presented (legibility, 
visibility, in one or more languages), 
additional information that a Member State may require (price, 
reimbursement conditions, etc.). 
(b) User leaflet 
In the same way, Articles 7 et seq. stipulate the contents of the obligatory 
leaflet (except in the case where all the information appears on packaging or 
the immediate packaging) and the method of presentation. 
(c) General provisions 
Finally, the proposal contains various provisions concerned with the procedure 
for monitoring labelling and package leaflets (marketing authorization and 
suspension of marketing authorization). If necessary (Article 13), the 
Commission will publish guidelines on these matters. 
2. Assessment 
This last directive completes the work already undertaken to harmonize, at 
European level, the contents of labels and leaflets. This step, which aims to 
ensure better information for patients in the Community, ought to be approved 
in principle. Detailed consultations concerning this proposal have taken 
place with industry, consumer organizations and representatives of doctors and 
pharmacists. 
Nevertheless, a number of changes would appear necessary in order to reduce 
certain excessive burdens placed on industry. In particular, it would be 
advisable to: 
- limit the mention of excipients solely to those excipients of which it is 
necessary to be aware to ensure safe and effective use of the medicine 
(Article 2), 
3 Directive 65/65/EEC of 26 January 1965, OJ No. 22, 9.2.1965, p.369/65 and 
Directive 89/341/EEC, OJ No. L 142, 25.5.1989, p.11 
DOC EN\RR\109304 - 26 - PE 145.361/fin. 
Or. FR 
- limit the list of information required for extremely 
packagings (Article 4(2)) without making reference to the 
concept of a dose is too vague, and limit this information 
to what is absolutely essential, 
small immediate 
dose, since the 
on blister packs 
- not to mention, in the context of the additional information that Member 
States could require (Article 6(2)), reimbursement conditions by social 
security organizations which, because of their complexity, is clearly 
impracticable. 
Furthermore, the invitation to the patient to communicate to his doctor or 
pharmacist the undesirable effects of a medicinal product should not be 
restricted to new medicines (Article 8(1)(e)). The concept of a medicine's 
newness varies from one country to another (depending on the date on which it 
was marketed) and, in general terms, the need for monitoring applies to all 
medicinal products. As far as pictograms are concerned (Article 8(3)), their 
use presupposes that they will be harmonized throughout the Community. 
Finally, the sanctions laid down in Article 11(3) and Article 12 in the event 
of failure to comply with the provisions of the directive, namely a refusal to 
grant market authorization or the withdrawal or suspension thereof, seem too 
harsh. A failure to comply with the provisions governing leaflets and 
labelling may amount to no more than a minor oversight. It is therefore 
rather harsh to impose a heavy penalty such as the suspension or withdrawal of 
market authorization, which applies throughout the Community, especially when 
the infringement has occurred at national level. 
In view of the number of pharmaceutical specialities and the complexity of the 
task, it would also appear that industry requires a transitional period for 
existing products. In this sense, the directive should be applied with 
immediate effect only to newly registered medicinal products. 
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Proposal for a directive on the labelling of medicinal products for human use 
and on package leaflets 
(Amendment No. 12) 
Article 1(2), first indent 
- 'name of the medicinal product' 
shall mean the name given to a 
medicinal product, which may be an 
invented name, a common name 
together with a trademark or the 
name of the manufacturer, or a 
scientific name together with a 
trademark or the name of the 
manufacturer; 
- 'name of the medicinal product' 
shall mean the name given to a 
medicinal product, which may be an 
invented name, a common name 
together with a trademark or the 
name of the manufacturer, or a 
scientific name together with a 
trademark or the name of the 
manufacturer; in the case of an 
invented name, this shall not be 
confused with the common name; 
(Amendment No. 13) 
Article 3(a)(d)(e)(ga) (new), and (j) 
(a) the name of the medicinal 
product, including or followed by 
the common name if the product 
contains only one active 
ingredient; 
(d) a list of the excipients; 
(e) the route and method of 
administration; 
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(a) the name of the medicinal 
product, including or followed 
by the common name if the prod-
uct contains only one active in-
gredient; when several pharmace-
utical specialities are desig-
nated by the same medicinal 
product name, they must be dif-
ferentiated by placing next to 
the name the pharmaceutical form 
preceded by the dose per unit 
on condition that it contains 
only one active ingredient and 
there are distinct doses for 
each pharmaceutical form; 
(d) the excipients that should be 
known about to ensure safe and 
effective use of the medicinal 
product; 
(e) the route and method of 
administration; 
(ga) ~t~h~e~-=l~e~n~g~t~h~~o~f~~t~~~·m~e--~a~n=d 
temperature for storage after 
being reconstituted for 
medicinal products presented 
in multiple doses and 
prepared extemporaneously; 
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( j) the name and address of the (j) The name and address of the 
person responsible for placing person responsible for placing 
the medicinal product on the the medicinal product on the 
market and, where different, of market and, where necessary, of 
the manufacturer; the manufacturer; 
(Amendment No. 14) 
Article 4(2)(3) (new) 
2. Paragraph 1 shall not apply to 
immediate packagings containing a 
single dose which are too small to 
carry all the particulars listed 
in paragraph 1. 
2. Paragraph 1 shall not apply to 
immediate packagings which are 
too small to carry all the 
particulars listed in paragraph 
1. 
3. In accordance with paragraph 1, 
blister packs shall bear only 
the name, concentration (where 
necessary>, expiry date and 
batch number. 
(Amendment No. 15) 
Article 7 
The inclusion in the packaging of 
medicinal prOducts of a package 
leaflet for the information of users 
shall be obligatory unless all the 
information required by Article 8 is 
directly conveyed on the outer 
packaging or on the immediate 
packaging. 
The inclusion in the packaging of 
medicinal products of a package 
leaflet for the information of users 
shall be obligatory unless all the 
information required by Article 8 is 
directly conveyed on the outer 
packaging or on the immediate 
packaging or unless the medicinal 
product may be administered only by 
a health professional. 
(Amendment No. 16) 
Article 8(1)(a), fourth indent 
name and address of the holder of 
the m~rketing authorization, 
where different, of 
manufacturer; 
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- name and address of the holder of 
the marketing authorization, and, 
where necessary, of the 
manufacturer; 
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(Amendment No. 17) 
Article S(l)(d), fifth indent 
the action to undertake in the 
case of overdose (symptoms, 
emergency procedures, antidotes), 
- the action to undertake in the 
case of overdose (symptoms, 
emergency procedures and antidotes 
where they exist together with an 
express recommendation not to use 
them except under medical 
control>, 
(Amendment No. 18) 
Article S(l)(e) 
(e) a description of the undesirable 
effects which can occur under 
normal use of the medicinal 
product, with indication if 
possible of their importance, 
and if necessary the action to be 
taken in such a case; when the 
medicinal product is new, the 
patient should be expressly 
invited to communicate any 
undesirable effect which is not 
mentioned in the leaflet to his 
doctor or to his pharmacist; 
(e) a description of the undesirable 
effects which can occur under 
normal use of the medicinal 
product, with indication if 
possible of their importance, 
and if necessary the action to 
be taken in such a case; the 
patient should be expressly 
invited to communicate any 
undesirable effect which is not 
mentioned in the leaflet to his 
doctor or to his pharmacist; 
(Amendment No. 19) 
Article 13, fifth indent (new) 
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CONCLUSIONS 
1. The aim of the three proposals for directives under consideration is the 
large-scale rationalization of the trade in medicinal products for human 
use in order to facilitate circulation of these products under conditions 
that provide maximum safety for the patient. 
In this sense, they comply with the objective of creating a single market 
in this sector which has so far been relatively closed. 
Labelling and package leaflets 
In order to ensure that patients are given the best information possible 
and that this information has universal application, the contents of labels 
and leaflets in respect of medicinal products must be harmonized. This 
proposal for a directive meets this essential requirement. 
However, this concern over information and safety should not result in 
placing on the manufacturer a requirement to provide an excessive amount of 
useless information (e.g. concerning excipients) and must be tailored to 
the type of packaging involved (e.g. extremely small packagings). 
Subject to the above proposed amendments - which the Committee on the 
Environment, Public Health and Consumer Protection is requested to take 
into account whose basic aim is to ensure that the European 
pharmaceutical industry, which must remain competitive, is not handicapped 
by excessive obligations, these three proposals for directives should be 
approved. 
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OPINION 
of the Committee on Budgets on the 
proposals for a Council directives on the rational use of 
medicinal products 
(COM(89) 607 final - C3-50/90) 
Dear Mr Chairman, 
At its meeting of 1 June 1990, the COmmittee on Budgets considered the above-
mentioned proposal. 
After considering the nature and the financial impact of this proposal, the 
committee decided to deliver a favourable opinion. 
Yours faithfully, 
(sgd) Thomas von der VRING 
Present: von der Vring, Chairman; Arias Canete, Boge, Colajanni, 
Colom I Naval, Elles, Kellett-Bowman, Langes, Lo Giudice, McCartin (for 
Forte), Miranda da Silva, Pasty, Theato, Tomlinson and Wy~n. 
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